CD19 and acute lymphoblastic leukemia: In a following phase I dose-escalation trial, 21 patients with relapsed or refractory ALL or non-Hodgkin lymphoma (NHL) were either treated with 1 × 106/kg/dose, 3 × 106/kg/dose or the entire CD19 CAR T cell product if the product did not meet the required dosage amounts.